Current and historical daily P/E ratio for NovoCure Ltd () from 2015 to Sep 25 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. NovoCure stock (NVCR) PE ratio as of Sep 25 2022 is 0.
More Details
NovoCure PE Ratio (TTM) Chart
NovoCure PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1255
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| NovoCure PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2022-09-25 | At Loss | 2022-07-22 | At Loss |
| 2022-09-23 | At Loss | 2022-07-21 | At Loss |
| 2022-09-22 | At Loss | 2022-07-20 | At Loss |
| 2022-09-21 | At Loss | 2022-07-19 | At Loss |
| 2022-09-20 | At Loss | 2022-07-18 | At Loss |
| 2022-09-19 | At Loss | 2022-07-15 | At Loss |
| 2022-09-16 | At Loss | 2022-07-14 | At Loss |
| 2022-09-15 | At Loss | 2022-07-13 | At Loss |
| 2022-09-14 | At Loss | 2022-07-12 | At Loss |
| 2022-09-13 | At Loss | 2022-07-11 | At Loss |
| 2022-09-12 | At Loss | 2022-07-08 | At Loss |
| 2022-09-09 | At Loss | 2022-07-07 | At Loss |
| 2022-09-08 | At Loss | 2022-07-06 | At Loss |
| 2022-09-07 | At Loss | 2022-07-05 | At Loss |
| 2022-09-06 | At Loss | 2022-07-01 | At Loss |
| 2022-09-02 | At Loss | 2022-06-30 | At Loss |
| 2022-09-01 | At Loss | 2022-06-29 | At Loss |
| 2022-08-31 | At Loss | 2022-06-28 | At Loss |
| 2022-08-30 | At Loss | 2022-06-27 | At Loss |
| 2022-08-29 | At Loss | 2022-06-24 | At Loss |
| 2022-08-26 | At Loss | 2022-06-23 | At Loss |
| 2022-08-25 | At Loss | 2022-06-22 | At Loss |
| 2022-08-24 | At Loss | 2022-06-21 | At Loss |
| 2022-08-23 | At Loss | 2022-06-17 | At Loss |
| 2022-08-22 | At Loss | 2022-06-16 | At Loss |
| 2022-08-19 | At Loss | 2022-06-15 | At Loss |
| 2022-08-18 | At Loss | 2022-06-14 | At Loss |
| 2022-08-17 | At Loss | 2022-06-13 | At Loss |
| 2022-08-16 | At Loss | 2022-06-10 | At Loss |
| 2022-08-15 | At Loss | 2022-06-09 | At Loss |
| 2022-08-12 | At Loss | 2022-06-08 | At Loss |
| 2022-08-11 | At Loss | 2022-06-07 | At Loss |
| 2022-08-10 | At Loss | 2022-06-06 | At Loss |
| 2022-08-09 | At Loss | 2022-06-03 | At Loss |
| 2022-08-08 | At Loss | 2022-06-02 | At Loss |
| 2022-08-05 | At Loss | 2022-06-01 | At Loss |
| 2022-08-04 | At Loss | 2022-05-31 | At Loss |
| 2022-08-03 | At Loss | 2022-05-27 | At Loss |
| 2022-08-02 | At Loss | 2022-05-26 | At Loss |
| 2022-08-01 | At Loss | 2022-05-25 | At Loss |
| 2022-07-29 | At Loss | 2022-05-24 | At Loss |
| 2022-07-28 | At Loss | 2022-05-23 | At Loss |
| 2022-07-27 | At Loss | 2022-05-20 | At Loss |
| 2022-07-26 | At Loss | 2022-05-19 | At Loss |
| 2022-07-25 | At Loss | 2022-05-18 | At Loss |
NovoCure PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
NovoCure Ltd
NAICS : 339112
SIC : 3845
Description
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.